IV infusion,
Adult
Bacteremia associated with intravascular line (due to
Chryseobacterium (Flavobacterium) species): 750 mg QD.
Bacterial prostatitis, chronic: 500 mg QD for 28 days.
Bacterial sinusitis, acute:
750 mg QD for 5 days or 500 mg QD for 10-14 days.
Bronchitis, chronic, acute bacterial exacerbation:
500 mg QD for 7 days.
Community acquired pneumonia:
500 mg QD for 7-14 days or 750 mg QD for 5 days.
Complicated urinary tract infection:250 mg QD for 10 days
for infections due to Enterococcus faecalis, Enterococcus
cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus
mirabilis, Pseudomonas aeruginosa.
Complicated urinary tract infection: 750 mg QD for 5 days
for infections due to Escherichia coli, Klebsiella
pneumoniae, Proteus mirabilis.
Infection of skin AND/OR subcutaneous tissue
(uncomplicated): 500 mg QD for 7-10 days.
Infection of skin AND/OR subcutaneous tissue (complicated):
750 mg QD for 7-14 days.
Inhalational anthrax, Post-exposure; Prophylaxis:
500 mg QD for 60 days.
Nosocomial pneumonia: 750 mg QD for 7-14 days.
Pyelonephritis, acute:
250 mg QD for 10 days for infections due to E coli; 750 mg QD for 5 days for infections due to E coli including cases with concurrent bacteremia.
Uncomplicated urinary tract infection: 250 mg QD for 3 days.
Pediatric
safety and efficacy in children under 18 years of age have not

hypersensitivity to levofloxacin, quinolone antibiotics ,

M: Diarrhea, nausea; headache;